Efficacy and safety of tegoprazan‐ and rabeprazole‐based concomitant therapies for Helicobacter pylori infection: Real‐world evidence
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Gastroenterology and Hepatology"
DOI: 10.1111/jgh.16719
Abstract: Tegoprazan, a novel potassium‐competitive acid blocker, has been approved for Helicobacter pylori eradication in Korea. We compared the efficacy and safety of tegoprazan‐ and rabeprazole‐based concomitant therapies for H. pylori eradication in real‐world clinical practice. read more here.
Keywords: tegoprazan; rabeprazole based; safety tegoprazan; tegoprazan rabeprazole ... See more keywords
Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study.
Sign Up to like & getrecommendations! Published in 2022 at "Gut and liver"
DOI: 10.5009/gnl220218
Abstract: Background/Aims Tegoprazan, a new, fast, and strong potassium-competitive acid blocker, has been approved for the treatment of gastric acid-related diseases in Korea. However, real-world clinical data regarding this drug are scarce. We aimed to compare… read more here.
Keywords: based triple; rabeprazole based; triple therapy; therapy ... See more keywords